Literature DB >> 2502063

Effects of biological response modifiers on ovarian carcinoma cell lines.

C Marth1, M Helmberg, I Mayer, L C Fuith, G Daxenbichler, O Dapunt.   

Abstract

Interferons have a mechanism of action different from chemotherapeutic agents. They modulate many physiologically important cellular functions and are a major building block in the network constructed by the biological response modifiers. Moreover, interferons are known to interact also with anticancer drugs to increase their therapeutic benefit. The aim of the present study was to evaluate the effects of interferon-gamma on cultured ovarian carcinoma cell lines. The growth of 3 out of 4 carcinoma cell lines (OVCAR-3, HTB-77, 2780 vs CRL-1572) was inhibited by interferon-gamma. The same cell lines which were growth inhibited also showed an induction of HLA-DR on their surface. CA-125 was found to be increased in 2 of them (OVCAR-3 and HTB-77) by interferon-gamma, whereas CEA was not detectable even after treatment. For HMFG-I, a shightly increased surface expression was induced on OVCAR-3 cells. HMFG-II expression was not significantly affected by interferon-gamma. The combined treatment with interferon-gamma and cisplatin, retinoic acid, or tumor necrosis factor alpha was studied on the ovarian carcinoma cells. For the combination with cisplatin we observed an additive or synergistic amplification of the antiproliferative activity, whereas tumor necrosis factor alpha resulted in a marked synergism in each case. In contrast to breast cancer cells retinoic acid and interferon-gamma acted synergistically only in one ovarian carcinoma cell line.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2502063

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  Interferon gamma and tumour necrosis factor alpha induce a synergistic antiproliferative response in human Ewing's sarcoma cells in vitro.

Authors:  F van Valen; W Winkelmann; S Burdach; U Göbel; H Jürgens
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

2.  Cellular distribution of retinoic acid receptor-alpha protein in serous adenocarcinomas of ovarian, tubal, and peritoneal origin: comparison with estrogen receptor status.

Authors:  C D Katsetos; I Stadnicka; J C Boyd; H Ehya; S Zheng; C M Soprano; H S Cooper; A S Patchefsky; D R Soprano; K J Soprano
Journal:  Am J Pathol       Date:  1998-08       Impact factor: 4.307

3.  Effects of interferon gamma on the proliferation and modulation of cell-surface structures of human ovarian carcinoma cell lines.

Authors:  V J Möbus; W Asphal; P G Knapstein; R Kreienberg
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

4.  Tumor-associated lymphocytes (TAL) are competent to produce higher levels of cytokines in neoplastic pleural and peritoneal effusions than those found in sera and are able to release into culture higher levels of IL-2 and IL-6 than those released by PBMC.

Authors:  G Mantovani; A Macciò; R Versace; M Pisano; P Lai; S Esu; M Ghiani; D Dessì; E Turnu; M C Santona
Journal:  J Mol Med (Berl)       Date:  1995-08       Impact factor: 4.599

5.  Cell-to-cell communication competence in simian virus 40-transfected rat ovarian cells is reduced following tumor selection.

Authors:  L S Stein; T H Welsh; V G Wilson; R C Burghardt
Journal:  In Vitro Cell Dev Biol       Date:  1992-06

6.  Cisplatin resistance is associated with reduced interferon-gamma-sensitivity and increased HER-2 expression in cultured ovarian carcinoma cells.

Authors:  C Marth; M Widschwendter; J Kaern; N P Jørgensen; G Windbichler; A G Zeimet; C Tropé; G Daxenbichler
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

7.  Identification of grade and origin specific cell populations in serous epithelial ovarian cancer by single cell RNA-seq.

Authors:  Andrew J Shih; Andrew Menzin; Jill Whyte; John Lovecchio; Anthony Liew; Houman Khalili; Tawfiqul Bhuiya; Peter K Gregersen; Annette T Lee
Journal:  PLoS One       Date:  2018-11-01       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.